Samsung Biologics Reaches ESG Milestone with 'Negligible Risk' Rating

Samsung Biologics has earned a 'Negligible Risk' rating in the latest Morningstar Sustainalytics ESG Risk Ratings assessment, the company announced. The contract development and manufacturing organization (CDMO) received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk'—the lowest of five risk categories. The result places Samsung Biologics among the top 0.5% of companies assessed in the pharmaceuticals industry.

What the Rating Means

Morningstar Sustainalytics, an independent ESG research and ratings provider, assesses approximately 16,000 companies worldwide based on their exposure to material ESG risks and how effectively those risks are managed. Under its methodology, scores below 10 indicate a negligible level of unmanaged ESG risk, with lower scores reflecting lower overall risk. Samsung Biologics' score of 9.0 therefore sits just inside the threshold for the lowest risk tier, signaling that the company's exposure to unmanaged ESG risks is minimal relative to industry peers.

Operational Improvements Behind the Upgrade

The improved rating reflects Samsung Biologics' continued efforts to strengthen ESG management across its business. According to the company, it has implemented initiatives to enhance environmental auditing, occupational health and safety, quality management, and business ethics, while reinforcing internal processes and oversight to identify and address potential risks. These measures span its manufacturing network and support functions, aligning with the broader operational discipline required of a global CDMO serving biopharma clients.

Executive Perspective

“Effective risk management is fundamental to how we operate as a global CDMO,” said John Rim, President and CEO of Samsung Biologics. "This recognition demonstrates the progress we have made in embedding responsible practices across our business. As we expand our global operations, we will continue to take a disciplined approach to managing risks and maintaining the trust of our clients and stakeholders."

Rim's comments underscore the dual imperative facing CDMOs: meeting rigorous quality and safety standards for clients while also satisfying investors and partners that ESG risks are being managed systematically. For Samsung Biologics, the upgrade is positioned as validation of that integrated approach.

A String of ESG Recognitions

The 'Negligible Risk' rating follows Samsung Biologics' recent 'A' rating in the 2026 MSCI ESG Ratings assessment. Earlier this year, the company also received the EcoVadis Platinum Sustainability Rating, placing it among the top 1% of companies assessed globally. Together, these assessments from three separate rating providers suggest a consistent pattern of recognition across environmental, social, and governance dimensions.

Manufacturing Footprint and Strategic Context

Samsung Biologics operates a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, plus 60,000 liters from its manufacturing facility in Rockville, Maryland, U.S., for a total global manufacturing capacity of 845,000 liters. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

The CDMO leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Its global manufacturing and commercial network spans Korea, the U.S., Europe, and Japan.

Industry Implications

For the CDMO sector, Samsung Biologics' ESG upgrade carries competitive weight. Pharmaceutical clients increasingly evaluate contract manufacturers not only on technical capability and capacity but also on sustainability and governance performance, which feed into their own supply-chain ESG reporting. A 'Negligible Risk' rating from Morningstar Sustainalytics—alongside an MSCI 'A' and EcoVadis Platinum—gives Samsung Biologics a differentiated position when bidding for long-term manufacturing contracts.

The recognition also arrives as the company prepares for further expansion with Bio Campus III. Maintaining a low ESG risk profile while scaling capacity is a challenge for any manufacturer, given the energy intensity and operational complexity of biologics production. Samsung Biologics' stated focus on environmental auditing, occupational health and safety, and quality management suggests it aims to keep risk controls proportional to growth.

What to Watch

Samsung Biologics has not disclosed specific targets or timelines tied to the rating upgrade. The company's ability to sustain its 'Negligible Risk' status will depend on how effectively it extends ESG oversight across new capacity and emerging modalities. For now, the rating adds to a growing set of third-party validations that the company is likely to cite in client conversations and investor communications as it competes in the global CDMO market.